Drugs / Navtemadlin
Trials 23
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT04190550 | Feb 2021 → Jun 2027 expected | acute myeloid leukemia | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03107780 | Jul 2018 → Aug 2025 | gliosarcoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1 | NCT03217266 | Jun 2018 → Aug 2023 | soft tissue sarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT03031730 | Jun 2018 → Jul 2024 | plasma cell myeloma, plasmacytoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT03041688 | Feb 2018 → Jun 2027 expected | acute myeloid leukemia | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02110355 | Dec 2014 → Dec 2018 | cancer, melanoma | Kartos Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02016729 | Apr 2014 → Apr 2017 | acute myeloid leukemia | Kartos Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01723020 | Dec 2012 → Mar 2017 | glioblastoma, plasma cell myeloma | Kartos Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT05705466 | Jun 2023 → Jun 2025 | non-small cell lung carcinoma | Kartos Therapeutics, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04835584 | May 2021 → Dec 2024 | chronic myeloid leukemia | Kartos Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04669067 | Mar 2021 → Nov 2024 | acute myeloid leukemia | Telios Pharma, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04502394 | Feb 2021 → Oct 2022 | B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma | Kartos Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04485260 | Jan 2021 → Oct 2022 | myelofibrosis | Kartos Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04640532 | Nov 2020 → May 2022 | myelofibrosis, primary myelofibrosis | Kartos Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04113616 | Sep 2019 → Sep 2023 | acute myeloid leukemia | Kartos Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT03787602 | Mar 2019 → Nov 2024 | cutaneous neuroendocrine carcinoma | Kartos Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT02825836 | Aug 2016 → Dec 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Telios Pharma, Inc. | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05027867 | Dec 2021 → Aug 2022 | small cell lung carcinoma | Kartos Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT04878003 | Apr 2021 → May 2024 | myelofibrosis, primary myelofibrosis | Kartos Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT03669965 | Jan 2019 → Apr 2022 | acquired polycythemia vera | Kartos Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05797831 | Jul 2023 → Aug 2025 overdue | endometrial cancer | Kartos Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03662126 | Jan 2019 → Dec 2023 | myelofibrosis with myeloid metaplasia | Kartos Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06479135 | Jun 2024 → Dec 2026 expected | myelofibrosis, primary myelofibrosis | Kartos Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 25 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | navtemadlin | “This study evaluates TL-895, a potent, orally available and highly selective irreversible tyrosine kinase inhibitor combined with navtemadlin (KRT-232), a novel oral small...” NCT04669067 ↗ |
| Known as | 2016-06-07: AMG-232 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3125702 ↗ |
| Known as | AMG 232 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01723020 ↗ |
| Known as | KRT-232 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03669965 ↗ |
| Known as | MDM2 INHIBITOR AMG-232 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3125702 ↗ |
| Action | Inhibit | “mouse double minute 2 homolog inhibitor” PMID 31253596 ↗ Jul 2019 |
| Modality | Small molecule | “novel oral small molecule inhibitor of MDM2” NCT03662126 ↗ |
| Route | Oral | “Given an an oral tablet in escalating doses.” NCT01723020 ↗ |
| Target | MDM2 | “AMG 232, an investigational oral, selective mouse double minute 2 homolog inhibitor” PMID 31253596 ↗ Jul 2019 |